Ludwig Burger
European Pharmaceuticals and Chemicals Correspondent at Reuters
Senior Correspondent at Thomson Reuters - views expressed are my own
Articles
-
6 days ago |
reuters.com | Patricia Weiss |Ludwig Burger
A general view of the BASF chemical industry company in Schwarzheide, Germany, November 1, 2022. REUTERS/Lisi Niesner/Pool/File Photo May 9 (Reuters) - BASF's (BASFn.DE), opens new tab agriculture unit is aiming to expand in Asia and global seed markets as it prepares for a stock market listing in about two years, a senior executive told Reuters.
-
1 week ago |
gurutrade.com | Ludwig Burger
ZURICH, May 8 (Reuters) - Adecco on Thursday said its hiring numbers have shown "modest positive momentum" since the start of April as the staffing company reported better-than-expected earnings for the first three months of the year. The Swiss company, which provides temporary and permanent staff to employers, reported operating income of 111 million euros ($125.71 million) for the three months to the end of March, ahead of analyst forecasts for 97 million euros.
-
1 week ago |
today.westlaw.com | Rachel More |Ilona Wissenbach |Ludwig Burger
FRANKFURT (Reuters) - Lufthansa Chairman Karl-Ludwig Kley will not run again as head of the German airline group's supervisory board, he told an annual investors' meeting on Tuesday, adding that the search for a successor in 2026 was on track.
-
2 weeks ago |
marketscreener.com | Ludwig Burger
FRANKFURT (Reuters) -Novartis released a more optimistic full-year earnings forecast on Tuesday, citing the strong growth of drugs such as Leqvio, Kisqali and Kesimpta during the first quarter. The Swiss drugmaker said in a statement that it expects 2025 operating income, adjusted for special items, to grow by a "low double-digit" percentage. It had previously projected "high single to low double-digit" growth this year, compared with a 22% increase in 2024.
-
2 weeks ago |
newsbulletin247.com | Ludwig Burger
by Ludwig BurgerFrankfurt (Reuters) – Novartis published more optimistic annual prospects on Tuesday, the group citing the solid growth of its drugs such as Leqvio, Kisqali and Kesmpta in the first quarter. The Swiss pharmaceutical group said in a statement anticipate an increase in the “two -digit low range” of its operating profit outside exceptional elements. Previously, he tapped on an increase between the “high fork with a figure and the two -digit low range” after a leap of 22% in 2024.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 332
- Tweets
- 124
- DMs Open
- Yes
RT @chemicalandi: The chemical industry’s path toward sustainability was never going to linear. @UmicoreGroup #EVs https://t.co/PILwpou1p…
It's early days for the science underpinning any use of #cgm in endurance sports. More to geek out on here: #continuousglucosemonitoring #glucose https://t.co/vluhQPbCpZ
Medical diagnostic tech is making the leap to elite sports. With @Sripootweets #cgm #continuousglucosemonitoring #glucose https://t.co/AsLxYgFkN4